In addition, ZEB2 acted as an oncogene to facilitate the progression of NSCLC [21–23], and our data supported that ZEB2 was aberrantly overexpressed in NSCLC tissues and cells, and high-expressed ZEB2 predicted a worse prognosis in NSCLC patients. Here, ZEB2 is linked to non-small cell lung carcinoma.